The deal had been signed for six weeks. The disclosure schedules were five hundred pages of redlines, footnotes, and small-print cross-references that the seller’s counsel had assembled over forty-eight hours in late February. The closing was on a Friday. On the Wednesday before closing, the seller’s general counsel pulled my client (the buyer) into a side conference room and handed him a thirty-seven-page supplement to the disclosure schedule. A pending wage-and-hour claim by a class of warehouse employees had been filed in Nevada the previous week. The complaint had been received. The seller’s officers were not aware of it at signing. The supplement disclosed it now.
My client’s first question was whether they could walk. My client’s second question was whether the supplement counted — meaning, whether the seller’s reps at closing would be qualified by the new disclosure or whether the new claim would be a breach of the unqualified signing reps. Those are different questions, and the merger agreement answered them differently. The first depended on the closing condition language. The second depended on a single phrase in Article VIII that the parties had negotiated for forty minutes the night before signing and then promptly forgotten about.
The phrase was the difference between a “bring-down” of the reps and a “bring-forward” of the disclosure schedule. Whether the deal documents permit the seller to supplement the disclosure schedule between signing and closing — and what the legal effect of that supplement is — is one of those negotiation choices that does not feel important at signing and turns out to be enormously important the first time something actually happens between signing and closing. It is worth being deliberate about, and the deal-lawyer practice on it is more divided than the form books suggest.
The two regimes
The bring-down approach is the older convention and the one that most form merger agreements default to. The seller represents and warrants in Article III that everything on the disclosure schedule is true as of the signing date. The closing condition in Article VII then requires that the reps continue to be true as of closing — sometimes qualified by a material adverse effect threshold, sometimes by an “in all material respects” qualifier, sometimes by the specific scheduled item. The disclosure schedule does not update. If new facts emerge between signing and closing, the seller has either breached a signing rep (giving the buyer an indemnification claim) or has failed the closing condition (giving the buyer a walk right), depending on whether the new fact existed at signing and was just unknown, or whether it arose later.
The bring-forward approach is the newer and increasingly popular convention. The seller has the right, between signing and closing, to deliver supplements to the disclosure schedule reflecting new facts that arise during the interim period. The supplements update the reps, so that the closing-date bring-down test is run against the supplemented schedule rather than the signing-date schedule. The supplement does not, however, retroactively qualify the signing reps for indemnification purposes — meaning that even though the closing condition is satisfied, the seller may still be exposed to an indemnification claim for the post-signing facts to the extent they constitute breaches of the signing reps.
The fight, in negotiation, is over whether the bring-forward supplement is “one-way” or “two-way.” A one-way supplement is the seller-friendly version: the supplement cures the closing condition (so the buyer cannot walk) but does not cure the indemnification claim (so the seller still owes for the post-signing breach). A two-way supplement is even more seller-friendly: the supplement cures both the closing condition and the indemnification, so the buyer’s only remaining recourse is to walk under a material-adverse-effect clause, which is — as the Chancery Court has reminded everyone over the past several years — a very difficult thing to do.
The buyer-friendly version is no supplement at all. The disclosure schedule freezes at signing. Anything that happens after that point is the seller’s risk, either as a closing condition or as an indemnification claim or both, depending on which provision applies. This is the historical default in private-target M&A, and it remains the default in deals where the buyer has meaningful negotiating leverage.
Why the choice matters more in 2026 than it did five years ago
Three things have made the bring-down-versus-bring-forward question more consequential in the current market.
The first is that signing-to-closing periods have lengthened. The HSR-cycle reforms in 2024 and the FTC’s heightened second-request rate have pushed the median interim period in transactions above the HSR threshold from forty-five days to closer to ninety, and that is in deals that do not draw an antitrust investigation. The longer the interim period, the more facts emerge in it, and the more often the bring-forward provision actually gets invoked. A bring-forward clause in a thirty-day signing-to-closing was largely theoretical. A bring-forward clause in a ninety-day signing-to-closing gets used.
The second is that the post-Akorn, post-Crispo Chancery line has narrowed the walk-right under MAC clauses to the point where the closing condition is, for most practical purposes, a high-friction remedy. If the buyer cannot easily walk on a MAC, the bring-down on the reps becomes the only meaningful closing-condition lever. A bring-forward provision that cures the bring-down without curing the indemnification can leave the buyer with no exit, only a damages claim against a post-closing seller whose stockholders are scattered to the four winds and whose escrow is capped at ten percent of purchase price. Recent Chancery opinions on closing-condition bring-downs have made the difference between the indemnification and the closing-condition uses of the supplement increasingly material to the buyer’s economic outcome.
The third is that rep-and-warranty insurance has reshaped the indemnification economics in a way that interacts oddly with the bring-forward question. Most RWI policies do not cover breaches of the reps that the seller knew about at signing — and increasingly do not cover breaches that the seller knew about at closing, including via a disclosure schedule supplement. A bring-forward supplement that the carrier reads as putting the seller on notice can carve the post-signing facts out of the policy entirely. The seller thinks the supplement protects it; the carrier reads the supplement as evidence that the loss was known to the insured. The buyer ends up with neither the closing-condition remedy (because the supplement cured the bring-down) nor the indemnification remedy (because the policy excludes the now-known matter), and the seller’s recourse against the carrier is foreclosed by the policy language. This trap is more common than it should be, and it is not always caught by the RWI broker reviewing the deal documents.
The drafting choices that matter
First, decide whether the supplement is permitted at all. If the buyer has negotiating leverage, the cleanest provision is no supplement — the schedule freezes at signing, and the interim period is the seller’s risk. If the seller insists on a supplement, the buyer should ask why and should price the concession.
Second, if the supplement is permitted, decide whether it cures the closing condition only or also cures indemnification. The default for a permitted supplement in most modern form agreements is the one-way version (cures closing condition, does not cure indemnification), but buyers in concentrated negotiations frequently extract a “neither” version — the supplement is delivered as a courtesy, but it does not cure either the closing condition or the indemnification, meaning the buyer can still walk on a failed bring-down and can still claim indemnification for the underlying breach. Sellers in concentrated negotiations push for the two-way version. The middle ground is the one-way version with an exception for matters arising from the seller’s gross negligence or willful conduct, which carves out the worst cases but leaves the supplement as the default rule.
Third, drop a notice-and-cure provision into the supplement clause. The buyer should be entitled to a defined period — five to ten business days — to review the supplement, request additional information, and either accept or contest it. A supplement that is delivered three days before closing, with the seller’s transmittal letter taking the position that the disclosure cures the bring-down, puts the buyer in an impossible position. The buyer either closes and gives up the closing-condition argument, or refuses to close and faces a specific-performance suit. A negotiated review window prevents the supplement from being weaponized at the last minute.
Fourth, align the supplement provision with the RWI policy. The carriers I have worked with in 2025 and 2026 will sometimes negotiate the “known matters” exclusion if the supplement provision is drafted to preserve the carrier’s subrogation rights against the seller. The negotiation has to happen at policy binding, not after, and the merger agreement and the RWI policy need to be drafted as a package. The mistake to avoid is signing the merger agreement first, binding the RWI policy second on the policy form the broker pulls off the shelf, and discovering at the first post-closing claim that the two documents have inconsistent treatment of post-signing disclosure supplements.
The fact pattern that triggers the fight
The fact pattern that surfaces this issue almost every time is the post-signing litigation filing. A complaint that is filed during the interim period, naming the target or a subsidiary, is the prototypical bring-forward problem. The seller’s officers did not know about it at signing — the cause of action may have existed for months or years, but the legal action that crystallizes it as a disclosable matter only happened on a Tuesday in week six. Whether the resulting schedule supplement cures the closing-condition rep, the indemnification rep, both, or neither is the question that the merger agreement has either answered cleanly or left to be litigated later.
The same fact pattern recurs with regulatory inquiries (a Wells notice, a state AG investigation, a Department of Labor audit), with key-customer terminations (the contract was at-will but the customer chose the interim period to exit), and with executive resignations (the CFO accepted a competing offer the week before closing). In each case, the relevant question is not “did the seller know” but “what does the deal document say about supplements to the schedule, and what effect does the supplement have.” The merger-agreement template work I have written about before treats this provision as one of the half-dozen most important paragraphs in the entire document, and I have not changed my mind about that.
The negotiation cost of getting the supplement provision right at signing is an hour of lawyer time. The negotiation cost of figuring it out three days before closing, with a wage-and-hour complaint sitting on the conference-room table, is a multiple of that. For a buyer, the bring-down-versus-bring-forward question is one of the cleanest examples in deal practice of a provision that gets little attention at the table and decides large dollars at the back end. Buy-side and sell-side practice on this issue diverges sharply by deal posture, and the right answer depends on what kind of leverage the buyer has — not on what the form book says.
If you are negotiating a merger or stock purchase agreement and trying to figure out where to land on the disclosure schedule supplement, feel free to reach out to my firm manager, Magda, at Magda@montague.law, or fill out our contact form. Mention you read this post.
